Compare Dr. Reddys with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ALEMBIC PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ALEMBIC PHARMA DR. REDDYS LAB/
ALEMBIC PHARMA
 
P/E (TTM) x 22.2 16.2 137.0% View Chart
P/BV x 3.3 3.7 89.1% View Chart
Dividend Yield % 0.7 1.0 69.6%  

Financials

 DR. REDDYS LAB   ALEMBIC PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ALEMBIC PHARMA
Mar-19
DR. REDDYS LAB/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,875664 433.0%   
Low Rs1,888412 457.8%   
Sales per share (Unadj.) Rs930.2208.7 445.7%  
Earnings per share (Unadj.) Rs117.431.0 378.8%  
Cash flow per share (Unadj.) Rs185.837.1 500.5%  
Dividends per share (Unadj.) Rs20.005.50 363.6%  
Dividend yield (eoy) %0.81.0 82.2%  
Book value per share (Unadj.) Rs844.4144.2 585.5%  
Shares outstanding (eoy) m166.07188.52 88.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.6 99.3%   
Avg P/E ratio x20.317.4 116.8%  
P/CF ratio (eoy) x12.814.5 88.4%  
Price / Book Value ratio x2.83.7 75.6%  
Dividend payout %17.017.7 96.0%   
Avg Mkt Cap Rs m395,496101,461 389.8%   
No. of employees `00022.0NA-   
Total wages/salary Rs m33,5627,467 449.5%   
Avg. sales/employee Rs Th7,032.8NM-  
Avg. wages/employee Rs Th1,527.9NM-  
Avg. net profit/employee Rs Th887.7NM-  
INCOME DATA
Net Sales Rs m154,48239,347 392.6%  
Other income Rs m3,37594 3,598.1%   
Total revenues Rs m157,85739,441 400.2%   
Gross profit Rs m31,7828,736 363.8%  
Depreciation Rs m11,3481,152 984.8%   
Interest Rs m889184 482.9%   
Profit before tax Rs m22,9207,493 305.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m438-93 -472.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,568 246.1%   
Profit after tax Rs m19,5005,844 333.7%  
Gross profit margin %20.622.2 92.7%  
Effective tax rate %16.820.9 80.5%   
Net profit margin %12.614.9 85.0%  
BALANCE SHEET DATA
Current assets Rs m111,10119,577 567.5%   
Current liabilities Rs m58,97314,896 395.9%   
Net working cap to sales %33.711.9 283.6%  
Current ratio x1.91.3 143.3%  
Inventory Days Days7990 88.4%  
Debtors Days Days9445 207.7%  
Net fixed assets Rs m101,24527,097 373.6%   
Share capital Rs m830377 220.2%   
"Free" reserves Rs m139,40626,811 520.0%   
Net worth Rs m140,23627,188 515.8%   
Long term debt Rs m22,0004,993 440.6%   
Total assets Rs m224,65647,778 470.2%  
Interest coverage x26.841.7 64.2%   
Debt to equity ratio x0.20.2 85.4%  
Sales to assets ratio x0.70.8 83.5%   
Return on assets %9.112.6 71.9%  
Return on equity %13.921.5 64.7%  
Return on capital %14.923.6 63.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67319,453 455.8%   
Fx outflow Rs m19,1046,065 315.0%   
Net fx Rs m69,56913,388 519.6%   
CASH FLOW
From Operations Rs m28,7048,120 353.5%  
From Investments Rs m-7,727-7,556 102.3%  
From Financial Activity Rs m-21,326590 -3,612.1%  
Net Cashflow Rs m-3141,153 -27.2%  

Share Holding

Indian Promoters % 25.5 74.1 34.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 2.9 186.2%  
FIIs % 35.3 9.1 387.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 13.9 110.1%  
Shareholders   75,885 49,328 153.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 22, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS